Abstract: The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.

Abstract: Provided herein are materials for the promotion of tissue regeneration, and methods of promoting tissue regeneration and wound healing therewith. In particular, materials displaying laminin-derived peptide sequences that facilitate cell migration into the material, and methods of use thereof, are provided.

Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.

Abstract: The present disclosure relates to conjugates of tertiary amine containing drugs. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making, and methods of using the same.

Abstract: The present invention discloses TRAIL receptor-binding agents, their therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present invention discloses methods for the treatment of cancer, comprising administrating a TRAIL receptor binding agent of the present technology, alone or in combination with a chemotherapeutic agent.

Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.

Abstract: The invention provides rF1 antibody antibiotic conjugates and methods of using same.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 43; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, wher

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

Abstract: Hereby, we disclose and claim, the concept, designs, enabling technologies, and utility for therapy of patients suffering from cancer, of a novel class of biomolecularly engineered, synthetic molecules: antibody-vaccine engineered constructs (AVEC). They comprise the main functional domains (antibodies and vaccines) and the supporting domains (linkers and reporters). Their mechanisms of actions rely upon antibody dependent redirecting, accelerating, and amplifying of the prophylactic or natural vaccination induced immune response (ADRAAVIR) from the initially elicited by vaccination towards the finally aimed by therapies. The routes of administration to the patients, pharmacokinetics, pharmacodynamics, pharmacogenomics, and therapeutic efficacies are resultant of those of the pertinent antibodies and vaccines assembled within AVEC.

Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.

Abstract: The present invention relates to a method for treating or preventing a disease, disorder or condition by administration of a polynucleotide, e.g. a modified RNA, encoding a peptide or protein related to this disease, disorder or condition. The present invention also relates to pharmaceutical compositions for use in such method.

Abstract: The present application provides methods of preventing and treating the toxic effects of exposure to organophosphate agents. In embodiments, targeted cationic liposome complexes delivering nucleic acid molecules encoding butyrylcholinesterase and a polyproline rich peptide are administered. Suitably, the administration is via inhalation or via aerosol. Also provided are cationic liposome complexes and methods of making the complexes for such administration.

Abstract: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg)l; (Lys)m; (His)n; (Orn)o; (Xaa)x with the majority of residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5?-to-3? direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.

Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.

Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.

Abstract: The invention provides a conjugate with fluorochrome moiety F coupled to a targeting moiety T. Moiety F is described by formula (I), and the targeting moiety T is characterised in that it has affinity to a tumour marker, such as an antibody or antibody fragment. The conjugate may be used for tumour diagnostics including photodetection of tumour nodules during resection surgery.

Abstract: Techniques are disclosed for medical diagnosis devices to facilitate the detection and measuring of emitted RF waves in living cell organisms characterized by chiral matter the electron transport chain of which includes spin polarized electrons. In accordance with an exemplary embodiment, an MF of appropriate magnitude is generated to cause the spin polarized electrons to reside at a higher energy level. The electron currents are then detected that are generated in the living cell organisms (and constituted by associated RF emissions) as the spin polarized electrons relax to an equilibrium state. The detecting of the electron currents is achieved using, for example, a receiver to detect an RF wave tuned to a frequency that is proportional to the magnitude of the MF at the fixed depth.

Abstract: The present invention relates to novel amphiphilic dendrimers, hereafter denoted Dendri-TAC. The present invention also relates to perfluorocarbon nanoemulsions stabilized by these amphiphilic dendrimers and their uses for in vivo diagnostic and/or for therapy, notably as theranostic tools, for detection and/or treatment of cancer.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: Compositions and methods for improved delivery of active agents to the brain are provided. The compositions typically include a nanocarrier, such as a polymeric nanoparticle, liposome, or nanolipagel or are in the form of a conjugate. The nanocarriers or conjugates typically include three components: a targeting moiety; a blood brain barrier blood-brain barrier modulator (BBB modulator), loaded into, attached to the surface of, and/or enclosed within a nanocarrier; and an additional active agent loaded into, attached to the surface of, and/or enclosed within a nanocarrier. The targeting moiety, which is typically conjugated to or otherwise dismodulator played on the surface of the nanocarrier, can be, for example, a moiety that preferentially or specifically targets brain cells or tissue, cancer cells, or a combination thereof.

Abstract: An implantable system is disclosed that includes an encapsulated housing including a radioactive source. The encapsulated housing is internally coated with a light-generating coating that converts the radioactive energy to light, that is then output in vivo to a photodiode positioned proximate to at least part of the encapsulated housing in vivo. The photodiode is configured to generate electrical current from the light, which electrical current is output to a power conditioning circuit that is configured to use the electrical current as an input electrical current and to output power to a load in vivo. The encapsulated may also be internally coated, at least in part, with a light directing coating that causes light to be directed toward an optical lens that focuses the light on the photodiode. The radioactive source may be a gas having a low half-life and which poses no health risk to a patient if released.

Abstract: The catalyst unit (1) for splitting a decontamination agent introduced into a containment for a decontamination process has at least one catalyst element (21). This catalyst element (21) first consists of a carrier material made of aluminum ceramics or activated carbon, and also of a catalytically active component in the form of nanoparticles, applied to the carrier material by means of chemical plating, and made of silver or silver oxide or of a silver and silver oxide mixture. The catalytically active component on the at least one catalyst element (21) is present in the range from 0.05 weight percent to 0.5 weight percent relative to the carrier material. The at least one catalyst element (21) has a catalytically effective surface in the range of up to 320 m2 per gram of used material, as a combination of carrier material plus applied catalytically active component. With the catalyst unit (1), an non-critical concentration of non-degraded decontamination agent of lower than 0.

Abstract: An apparatus for sterilization of objects or materials comprises an enclosure for containing a gaseous atmosphere; an acoustically transparent platform located within the enclosure for supporting the objects or materials to be sterilized; one or more non-contact ultrasound transducers positioned within the enclosure and spaced from the platform; and an electric power amplifier for exciting the one or more transducers.

Abstract: A low-pressure system for cleaning items includes a tub, at least one steam head mounted in the tub having a rotatable nozzle configured to direct steam towards the bottom of the tub. The steam generator is in fluid communication with both the first steam head and the second steam head. A valve including a foot pedal mounts in fluid communication between the steam generator and each steam head. The steam generator connects to a water and power source for generating dry steam at a temperature exceeding 300° F. and at a pressure of less than 150 psi. The dry steam maintains a dryness fraction of 0.4-0.9 at all points within the system.

Abstract: Disclosed is an antibacterial mat, of the type conventionally disposed at the entrance of an enclosed space, suitable to be trodden on by persons entering said enclosed space, which comprises: a planar cover that can be penetrated by ultraviolet (UV) radiation; and means for generating UV radiation, the means for generating UV radiation being concealed by the cover.

Abstract: The device for cleaning a hearing aid by contact with a liquid includes a cleaning cavity suitable for receiving the end piece of the hearing aid and that is provided, at the bottom of same, with an opening for discharging the liquid. The cleaning cavity is defined laterally by an inner skin surrounded by an outer skin, the outer skin including an injector for the liquid while the inner skin defines, at the base of same, an opening overhanging the bottom and allowing the liquid to pass into the cleaning cavity. The invention also concerns an assembly includes the cleaning device and a reloading unit, the reloading unit being suitable for filling a tank of the cleaning device.

Abstract: A sterilization system includes a sterilization device and a control device. The sterilization device includes at least one emitter configured to emit ultraviolet energy, and at least one localization system configured to determine positional and spatial relation between the sterilization device and a target area. The control device includes a storable medium and a processor in communication with the emitter and the localization system. The control device is configured to scan the target area, via the localization system, execute a sterilization process based on a sterilization profile, via the at least one emitter, extrapolate data received from the localization system in an iterative process, via the processor, and generate a sterilization map of the target area indicative of areas within the target area determined to be sterilized based on the extrapolated data.

Abstract: A table-top heat-activated aroma diffuser includes a light-transmissive housing including a first opening located on one side thereof and a second opening located on an opposite side thereof, a heat-transfer unit mounted in the first opening of the light-transmissive housing, a heater mounted to a bottom side of the heat-transfer unit for heating an aroma capsule being placed on the heat-transfer unit to release an aromatic vapor, and a light-emitting device mounted inside the light-transmissive housing for creating halo light soft decorative effect.

Abstract: A device for releasing volatile substances, including a container that contains a solid substrate impregnated with volatile substances and a clamping element. The device also includes at least two retaining arms of the solid substrate. The arms extend substantially from the center of the container and towards the larger exterior edge of the container. The device allows the deformation of the solid substrate to be contained since the arms force the solid substrate to maintain the position thereof in contact with the arms.

Abstract: Microporous materials that include thermoplastic organic polyolefin polymer (e.g., ultrahigh molecular weight polyolefin, such as polyethylene), particulate filler (e.g., precipitated silica), and a network of interconnecting pores, are described. The microporous materials of the present invention possess controlled volatile material transfer properties. The microporous materials can have a density of at least 0.8 g/cm3; and a volatile material transfer rate, from the volatile material contact surface to the vapor release surface of the microporous material, of from 0.04 to 0.6 mg/(hour*cm2). In addition, when volatile material is transferred from the volatile material contact surface to the vapor release surface, the vapor release surface is substantially free of volatile material in liquid form.

Abstract: A plug-in fragrance dispenser contains: a body, an electric plug, a heating element, a thermal transfer element, and a holder. The electric plug is electrically connected with a power source, and the body is coupled with the electric plug and includes a first orifice, a first connection part, and a second connection part. The first connection part is connected with the second connection part, the first connection part has an accommodation lid and a surround sleeve, and the surround sleeve has the first orifice defined on a top thereof. The accommodation lid has a second orifice in which the electric plug is accommodated, the second connection part has a support seat and a first cap formed on an upper end of the support seat and connecting with a bottom of the surround sleeve, wherein the support seat is housed in the accommodation lid.

Abstract: A volatile substance evaporation element including a rod impregnated with volatile substances, the rod being made of sintered wood. The porosity of the rod varies between its core and its surface, the porosity of said rod being lower on its surface than in its core, making it possible to increase the capacity of the core of the evaporation element to act as a receptacle for volatile substances.

Abstract: Aqueous compositions, methods of manufacturing such aqueous compositions, and methods of removing reducing and/or suppressing malodours using such aqueous compositions are described. These compositions utilize a combination of hydrogen peroxide, a source of copper II, nonionic surfactant and alcohol to provide a highly effective and stable malodour removing, reducing and/or suppressing composition. The compositions are particularly useful as aerosol compositions for effective malodour removal, reduction and/or suppression in particular malodours from open sites such as landfill and in closed domestic environments such as the home. Also described is a stabilized hydrogen peroxide solution, which is stable on the addition of copper (II) salts.

Abstract: This document describes a high intensity air purifier, a super oxidation purifier, and a controller for controlling operation of any of various purification systems. The air purifier includes an air purifier system coupled within a housing having an air inlet and an air outlet. The air purifier system includes a pre-filter coupled to the air inlet, an axial fan for receiving and forwarding air from the air inlet. The air purifier further includes a UV reaction chamber having a UV-light source for providing UV light to the forwarded air from the air inlet and a reflective lining to reflect the provided UV light, to provide UV purified air from the UV reaction chamber. The air purifier further includes a chemical catalyst cartridge for receiving the UV purified air from the UV reaction chamber, for further purifying the UV purified air, and a post filter coupled to the air outlet.

Abstract: The present technology relates to composites, apparatuses, systems, and methods that are based on a photocurable composite useful for stabilizing, supporting, or otherwise healing an injured limb. The photocurable composite includes a light-curable resin and a filler material, where the light-curable resin includes about 50 vol % to about 99 vol % (based on the volume of the light-curable resin) of an acrylate-functionalized oligomer, wherein the backbone of the oligomer comprises a polyurethane, a polyether, a polyester, or a combination of any two or more thereof; about 1 vol % to about 50 vol % of a radical-reactive diluent; about 0.001 vol % to about 2 vol % of a photoinitiator; and optionally about 0.05 to about 25 vol % of a surface cure protection agent.

Abstract: A process for agglomerating superabsorbent particles, wherein polymer particles having a particle size of 250 ?m or less are dispersed in a hydrophobic organic solvent, the dispersed polymer particles are mixed with an aqueous monomer solution, the amount of unneutralized monomer applied with the monomer solution being from 0.5% to 80% by weight, based on the dispersed polymer particles, and the monomer solution is polymerized.

Abstract: A fluid absorbing pressure sensitive adhesive composition and adhesive articles including the fluid absorbing adhesive that have particular utility in the medical field, and in particular, for use with wound dressings is provided. The adhesive composition has superior fluid handling capacity, moisture vapor transmission and skin adhesion. Also described are dressings, cover drapes, and/or sealing components for negative pressure wound therapy applications. The articles include a thin film having a layer of a breathable hydrocolloid adhesive. When used in negative pressure wound therapy applications, the articles are breathable and fluid absorbing.

Abstract: A process for agglomerating superabsorbent particles, wherein polymer particles having a particle size of 250 ?m or less are dispersed in a hydrophobic organic solvent, the dispersed polymer particles are mixed with an aqueous monomer solution, the total amount of water applied to the dispersed polymer particles being at least 100% by weight, based on the dispersed polymer particles, and the monomer solution is polymerized.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: Aspects of the present invention provide implants for augmentation, stabilization, or defect reconstruction of bone tissue, comprising a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following: one or more polylactic acid isomer; one or more polyglycolic acid isomer; and/or allogenic bone material, or similar compound.

Abstract: Hydrophilic coatings including a base coat layer and a top coat layer wherein at least one of the base coat and top coat compositions that form the hydrophilic coatings comprises a diacrylate compound have a number average molecular weight less than 1000.

Abstract: The present invention includes a growth factor profile, connective tissue matrix constituents, and immunoprivileged status of equine placental tissue extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render equine placental tissue an ideal source for biological scaffolds for xenotransplantation, and optionally adding at least one of: one or more block-copolymers, one or more osteogenic agent or one or more osteoinductive agents.

Abstract: The presently disclosed subject matter provides for decellularized extracellular matrix (dECM) compositions for reconstructing mucosal tissue of trachea and methods of using the same. In certain embodiments, the composition can be a pre-gel containing dECM derived from tracheal mucosal tissue; a hydrogel obtained by gelling the pre-gel; or a vitrified membrane obtained by drying the hydrogel.

Abstract: The present disclosure relates to a method for preparing a nerve conduit, more particularly to a method for preparing a porous nerve conduit having micropores formed in microchannels and the nerve conduit prepared according to the present disclosure can be usefully used in in-vitro and in-vivo researches on nerves.